Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
2022 · New England Journal of Medicine · 2,396 citations
https://doi.org/10.1056/nejmoa2203690
Q
Qiang Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
934
Papers
35.8K
Citations
88
h-index
405
i10-index
Qiang Liu is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Cancer-related molecular mechanisms research & MicroRNA in disease regulation & Breast Cancer Treatment Studies. The author has an h-index of 88, co-authored 794 publications.
ORCID: 0000-0002-5451-4862Papers by this author
worksPrimary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
2021 · Annals of Oncology · 702 citations
https://doi.org/10.1016/j.annonc.2021.05.801
Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer
2023 · Cell Host & Microbe · 302 citations
https://doi.org/10.1016/j.chom.2023.04.010
LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer
2020 · Nature Communications · 190 citations
https://doi.org/10.1038/s41467-020-19349-w
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 <sup>+</sup> Breast Cancer Growth and Metastasis
2012 · Science Translational Medicine · 183 citations
https://doi.org/10.1126/scitranslmed.3003601
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
2020 · Journal for ImmunoTherapy of Cancer · 173 citations
https://doi.org/10.1136/jitc-2020-000696
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat